The Australian medical community is abuzz with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in clinical trials for addressing obesity. This https://bookmarkingalpha.com/story21763794/retatrutide-australia-a-new-prospect-for-weight-management